DARE Dare Bioscience, Inc.

NEUTRAL Impact: 4/10 DEFA14A
Horizon days Filed Jun 1, 2026 Processed 11d 10h ago SEC 0001493152-26-026666
Proxy solicitation materials
Latest settled — T+1d ⚠ clustered
DARE ▼ -4.21% at T+1d
NEUTRAL call ✗ call lost -4.21% · α vs SPY -3.48% · entry $2.14 → $2.05
Next anchor: T+5d due 5d ago
Currently $2.02 · -5.61% from $2.14 entry
Entry anchored
Jun 1, 2026
via day open
T+1d
-4.21%
call -4.21% · α -3.48%
$2.05
settled 11d ago
T+5d
call — · α —
due 5d ago
T+20d
call — · α —
in 17d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Dare Bioscience filed a DEFA14A supplement to its proxy statement, disclosing the engagement of Okapi Partners LLC as an independent proxy solicitor for the June 11, 2026 annual meeting. The $15,000 fee plus expenses is a routine administrative step, but the engagement of a professional solicitor at a micro-cap biotech suggests management anticipates a contested vote or low retail turnout, warranting attention.

Actionable Insight

The hiring of a professional proxy solicitor at a $33M market cap company signals management is concerned about vote counts—likely due to activist pressure or low retail participation. Monitor for any dissident proxy materials (DFAN14A) ahead of the June 11 meeting; a contested vote could drive volatility.

Key Facts

  • Engaged Okapi Partners LLC as proxy solicitor for $15,000 fee plus expenses
  • Annual meeting scheduled for June 11, 2026
  • Supplement filed June 1, 2026, supplementing April 28, 2026 proxy statement
  • Management paying entire cost of solicitation; directors/employees may solicit without extra compensation

Financial Impact

$15,000 fee plus additional expenses for proxy solicitation services

operating expenses

Risk Factors

  • Potential activist campaign or dissident slate could emerge before the meeting
  • Low institutional ownership may amplify retail vote uncertainty
  • Proxy fight costs could strain cash reserves for a micro-cap biotech

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001493152-26-026666
Document: 0001493152-26-026666-index-headers.html0001493152-26-026666
Document: 0001493152-26-026666-index.html0001493152-26-026666
Document: 0001493152-26-026666.txt0001493152-26-026666
12 reports for DARE
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+60▲ +27.03%Mar 12, 2026
Filters
Rows
Reports for DARE — sortable, filterable
Type Now
Jun 12, 2026
today
8-K
NEUTRAL ★ 2/10
$2.03 awaiting T+1awaiting T+1$2.02 (−0.25%)
Jun 1, 2026
11d ago
DEFA14A
NEUTRAL ★ 4/10
$2.14 $2.05▼ −4.21%▼ −3.48%$2.02 (−5.61%)
Jun 1, 2026
11d ago
DEFA14A
NEUTRAL ★ 2/10
$2.19 $2.14▼ −2.28%▼ −2.43%$2.02 (−7.76%)
May 14, 2026
29d ago
Press Release
NEUTRAL ★ 5/10
$2.17 $2.11▼ −2.77%▼ −2.70%$2.02 (−6.91%)
Apr 28, 2026
6w ago
DEFA14A
NEUTRAL ★ 2/10
$2.10 $2.28▲ +8.57%▲ +7.55%$2.02 (−3.81%)
Apr 22, 2026
7w ago
8-K
NEUTRAL ★ 2/10
$2.27 $2.12▼ −6.61%▼ −6.21%$2.02 (−11.01%)
Apr 20, 2026
7w ago
8-K
BEARISH ★ 5/10
$2.36 $2.27▲ +3.81%▲ +4.83%$2.02 (+14.41%)
Apr 17, 2026
8w ago
8-K
NEUTRAL ★ 2/10
$2.87 $2.36▼ −17.77%▼ −17.12%$2.02 (−29.62%)
Apr 13, 2026
8w ago
8-K
BEARISH ★ 6/10
$1.75 $1.79▼ −2.29%▼ −1.51%$2.02 (−15.43%)
Mar 26, 2026
11w ago
Press Release
MIXED ★ 5/10
$1.55 $1.83▲ +18.06%▲ +18.42%$2.02 (+30.32%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (53h 15m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access